Spastic ataxia-corneal dystrophy syndrome

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Spastic ataxia-corneal dystrophy syndrome | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | Neurology, Ophthalmology |
| Symptoms | Spasticity, ataxia, corneal dystrophy |
| Complications | N/A |
| Onset | Childhood |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Genetic testing, neurological examination, ophthalmological examination |
| Differential diagnosis | Other forms of ataxia, other corneal dystrophies |
| Prevention | N/A |
| Treatment | Physical therapy, occupational therapy, supportive care |
| Medication | N/A |
| Prognosis | Variable, depends on severity |
| Frequency | Rare |
| Deaths | N/A |
A rare genetic disorder affecting the nervous system and eyes
Spastic ataxia-corneal dystrophy syndrome is a rare genetic disorder characterized by a combination of neurological and ocular symptoms. This condition is primarily marked by spasticity, ataxia, and corneal dystrophy.
Presentation[edit]
Individuals with spastic ataxia-corneal dystrophy syndrome typically present with a range of symptoms that affect both the nervous system and the eyes.
Neurological Symptoms[edit]
The neurological manifestations of this syndrome include:
- Spasticity: Increased muscle tone leading to stiffness and difficulty with movement.
- Ataxia: Lack of voluntary coordination of muscle movements, which can affect gait and balance.
- Hyperreflexia: Exaggerated reflex responses.
- Muscle weakness: Particularly in the lower limbs, contributing to mobility issues.
Ocular Symptoms[edit]
The primary ocular symptom associated with this syndrome is:
- Corneal dystrophy: A group of eye disorders in which abnormal material accumulates in the cornea, leading to vision impairment. This can cause symptoms such as blurred vision, eye pain, and sensitivity to light.
Genetics[edit]
Spastic ataxia-corneal dystrophy syndrome is believed to be inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder. The specific genetic mutations responsible for this syndrome have not been fully elucidated, but they are thought to affect proteins involved in nerve and corneal function.
Diagnosis[edit]
Diagnosis of spastic ataxia-corneal dystrophy syndrome is based on clinical evaluation, family history, and specialized tests. These may include:
- Neurological examination: To assess muscle tone, reflexes, and coordination.
- Ophthalmologic examination: To evaluate the cornea and detect any dystrophic changes.
- Genetic testing: To identify mutations in genes associated with the syndrome.
Management[edit]
There is currently no cure for spastic ataxia-corneal dystrophy syndrome. Management focuses on alleviating symptoms and improving quality of life. Treatment options may include:
- Physical therapy: To improve mobility and reduce spasticity.
- Occupational therapy: To assist with daily activities and enhance independence.
- Medications: Such as muscle relaxants to manage spasticity.
- Regular eye examinations: To monitor and manage corneal changes.
Prognosis[edit]
The prognosis for individuals with spastic ataxia-corneal dystrophy syndrome varies depending on the severity of symptoms and the effectiveness of management strategies. Early intervention and supportive care can help improve outcomes and quality of life.
See also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian